The effect of zolpidem-CR on the suicide item of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia and suicidal ideation: Lessons learned.
Hypnotic
Observer-rated
Self-report
Journal
Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
27
07
2023
revised:
16
10
2023
accepted:
26
10
2023
medline:
6
12
2023
pubmed:
6
11
2023
entrez:
3
11
2023
Statut:
ppublish
Résumé
The REST-IT study found the addition of zolpidem-controlled release (CR) provided a significant reduction in observer-rated measurement of suicidal ideation (the Columbia Suicide Severity Rating Scale) in 103 depressed outpatients with insomnia and suicidal ideation, but without significant change in a self-report measure of suicidal ideation (the Scale for Suicide Ideation). This secondary analysis of the REST-IT data examined the suicide item of another observer-rated scale, the Hamilton Rating Scale for Depression (HRSD), further clarifying the impact of insomnia-focused treatment on suicidal ideation. This analysis established a significant advantage for zolpidem-CR compared with placebo on the HRSD suicide item.
Identifiants
pubmed: 37922732
pii: S0165-1781(23)00526-7
doi: 10.1016/j.psychres.2023.115576
pii:
doi:
Substances chimiques
Zolpidem
7K383OQI23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115576Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. McCall reports royalties from Wolters Kluwer and payments from Carelon and Idorsia as a scientific advisor. Dr Krystal reports Options: Neurawell, Big Health Research Grants: Janssen Pharmaceuticals, Axsome Pharmaceutics, Attune, Harmony, Neurocrine Biosciences, Reveal Biosensors, The Ray and Dagmar Dolby Family Fund, and the National Institutes of Health Consulting: Axsome Therapeutics, Big Health, Eisai, Evecxia, Harmony Biosciences, Idorsia, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Millenium Pharmaceuticals, Merck, Neurocrine Biosciences, Neurawell, Otsuka Pharmaceuticals, Sage, Takeda Dr Benca is a consultant to Eisai, Idorsia, Genentech, Merck, Jazz, Sage, and receives research support from Eisai No other authors have disclosures